The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > Research services > Insulin resistance – diabetes

Insulin resistance – Diabetes

Diabetes mellitus is a chronic metabolic disorder, caused by a failure of the body to produce insulin and/or an inability of the body to respond adequately to circulating insulin. The World Health Organization estimates that 346 million people worldwide have diabetes.

Type 2 diabetes and its complications such as diabetic neuropathy, retinopathy and macrovascular complications (cardiovascular disease and stroke) have a significant economic impact on both the developed and emerging countries worldwide.
Lipid, lipoprotein and glucose metabolic disorders are interconnected and cause several human diseases. This underlines the importance of being able to measure both direct and indirect effects of medicines in integrated animal models and/or panels of complementary models of glucose, lipid and lipoprotein disturbances.

KEY BENEFITS

  • Outstanding scientific expertise and consultancy
  • Innovative in-house diet-induced animal models
  • Gold-standard methods (euglycemic hyperinsulinemic clamp, hyperglycemic clamp) and novel in-house techniques
  • Dedicated research platform to evaluate the therapeutic potential of your compounds in type 2 diabetes, as well as other metabolic disorders and cardiovascular complications
  • Customized research solutions to target your needs

Animal Experimental Models

Nutrional animal models

Differentiate your incretin-based therapies and SGLT2 inhibitors in DIO mice

Differentiate your drug against competitors through in vivo experiments to unmask specific benefits/scientific advantages. ico-link

r346_16_glp-1_analogues_and_sglt2_inhibitors_in_dio_mice_-__physiogenex_thumbnail

High fat diet mouse (60% fat)

A reference mouse model dedicated to diabetes and obesity studies. ico-link

High fat diet mouse model 60%

High fat diet CETP-apoB100 mouse

In-house model: a transgenic mouse model expressing both human apoliprotein B and CETP. The model fed a high fat diet exhibit diabetes and dyslipidemia. ico-link

CETP ApoB100 mouse high fat diet model

Diet Induced Obesity (DIO) rat (40% fat)

A diet-induced rat model dedicated to obesity / insulin resistance studies. More info

Diet induced Obesity (DIO) rat model

Diet Induced Obesity (DIO) mouse (60% fat)

A diet-induced mouse model that exhibit obesity, viscerae adiposity, insulin resistance and hyperinsulinemia. A model to study pre-diabetes, type 2 diabetes and obesity. More info

Diet-induced obesity (DIO) mouse model

Insulin Resistant and dyslipidemic hamster model

In-house model: a high fat fed hamster model with insulin resistance/diabetes, dyslipidemia and hepatic steatosis. More info

Insulin resistant and dyslipidemic hamster model

Insulin Resistant rat

First-in-class rat model fed a high fat, medium fructose, cholic acid diet combining visceral obesity, insulin resistance and NAFLD. More info

Insulin resistant rat

Insulin resistant hypertensive rat

In-house model: a high salt and sucrose diet fed rat that displays major features of the onset of diabetic nephropathy in association with insulin resistance and hypertension. More info

Insulin resistant hypertensive rat model

Genetic animal models

Ob/ob mouse

A leptin-deficient mouse model for type 2 diabetes, obesity.

Ob / ob mouse

Db/db mouse

A leptin-deficient mouse model to study diabetes, obesity and diabetic dyslipidemia.

Zucker Diabetic Fatty (ZDF) rat

A genetic rat model for the study of type 2 diabetes, hyperglycemia, insulin resistance, hyperinsulinemia, hypertriglyceridemia, hypercholesterolemia and cardiovascular or renal complications.

Zucker Diabetic Fatty (ZDF) rat

Zucker fatty rat

A genetic rat model of obesity, insulin resistance and hypertension.

Goto-Kakizaki (GK) rat

A non-obese rat model for type 2 diabetes. A high fat diet can modulate the phenotype.

Other animal models

Streptozotocin (STZ) mouse or rat

A chemically induced pancreatic necrosis to produce a diabetic model.

Technical platform / Read-Outs

In vivo screening and profiling
Glucose homeostasis
Glucose tolerance test – GTTico-linkYesYes
Insulin tolerance test – ITTico-linkYesYes
Euglycemic hyperinsulinemic clampico-linkGold-standard method
Hyperglycemic clampico-linkGold-standard method
Whole body glucose turnoverico-linkYesYes
In vivo individual tissue glucose uptakeico-linkGold-standard method
Lipid metabolism
Lipid tolerance testico-linkYesYes
Whole body FFA turnoverico-linkGold-standard method
In vivo individual tissue FFA storage rateico-linkGold-standard method
Lipogenesis in vivo YesYes
Heart metabolism
In vivo Lipid cardiac metabolismYesYes
In vivo Glucose cardiac metabolismYesYes
Ex vivo screening
Muscles / Adipocytes ex vivo glucose uptakeico-linkIn-house validated technique
Muscles / Adipocytes ex vivo FFA oxydationico-linkIn-house validated technique
Adipocytes ex vivo lipolysisico-linkYesYes
Biochemistry / Biomarkers, Cardiometabolic parameters and other services
Biochemistry / Biomarkersico-linkYesYes
HistopathologyYesYes
Cardiometabolic parametersYesYes
Basic services Body weight, Food intake, Lipid homeostasis, Blood collection and tissue harvesting
Non invasive imaging services
Preclinical nuclear imaging servicesBenefit of unique imaging services with innovative translational tracers associated with gamma imager, nanoSPECT/CT, nanoPET/CT, ultrasound imaging devices